source
- Inhibrx reports 44% response rate when paired with Keytruda in head-and-neck cancer Phase 2 trialInhibrx Biosciences said its experimental agent INBRX-106 boosted the activity of Merck's Keytruda in a Phase 2 study of a head-and-neck cancer. The combination achieved a 44% overall response rate…
- GSK partners with Sino Biopharma to expand access to hepatitis B drug bepirovirsen in ChinaGSK announced a marketing agreement with Sino Biopharmaceutical to distribute its experimental hepatitis B therapy bepirovirsen in China. Sino's subsidiary will purchase a supply of the drug and u…